The approach of combining the pharmacological targeting of one pathway together with the genetic targeting of a cooperating pathway is termed a “synthetic lethal” approach to cancer therapy (Figure 4), and is exemplified by the enhanced susceptibility of cancer cells lacking HR proteins BRCA1 and BRCA2 to death caused by G4-stabilizing ligands [17,70]. This evidence concerns the gene BRCA2 and cancer.